文献速递乳腺癌放疗放疗物理与技术

乳腺癌区域淋巴结阳性患者术后放疗与CDK4/6抑制剂同步对比序贯的多中心安全性与毒性研究

Concurrent Versus Sequential Postoperative Radiotherapy and CDK4/6 Inhibitors in Breast Cancer with Positive Regional Nodes: A Multi-Center Safety and Toxicity Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-10-22

该多中心真实世界回顾性队列研究纳入364例淋巴结阳性、可手术的HR+/HER2-乳腺癌患者,比较术后放疗与CDK4/6抑制剂同步对比序贯给药的安全性与毒性。经倾向性评分匹配后每组87例,主要终点永久性停用CDK4/6i在匹配前后组间均无显著差异,≥3级药疹在同步组数值上更高但匹配后仅达边缘统计学意义,其余严重毒性无显著差异。结论认为同步方案安全性总体可控,但需密切监测毒性。

要点

  • 匹配前后CDK4/6i永久停药率组间均无显著差异。
  • 同步组≥3级药疹数值更高,匹配后仅边缘显著且均位于放疗野外。
  • sRILI、间质性肺炎、≥3级放射性皮炎及血液毒性组间无显著差异。

核心结论

  • 术后放疗与CDK4/6抑制剂同步给药的安全性和耐受性总体可控。
  • 因两组均观察到因≥3级毒性而停药,联合治疗全程需密切监测毒性并综合管理。

研究设计与样本

  • 采用倾向性评分匹配平衡基线协变量,匹配后每组87例。
  • 主要终点为永久性停用CDK4/6i,次要终点包括减量、换药、≥3级毒性和症状性放射性肺损伤(sRILI)。

主要发现

  • CDK4/6i停药率匹配前为10.4% vs 8.4%(P=0.536),匹配后为10.3% vs 9.2%(P=0.798),均无显著差异。
  • 减量与换药在匹配前后两组间均无显著差异。
  • 未匹配队列单因素分析显示同步组≥3级药疹发生率显著更高(4.3% vs 0.4%,未校正P=0.013),PSM协变量平衡后为4.6% vs 0.0%(未校正P=0.059),仅达边缘统计学意义。
  • 所有≥3级药疹均发生在放疗野外,表现为累及躯干和四肢的弥漫性斑丘疹,符合CDK4/6i相关超敏反应。
  • sRILI、间质性肺炎、≥3级放射性皮炎、≥3级腹泻及血液学毒性在匹配前后均无显著组间差异。

临床怎么用

  • 对于淋巴结阳性、可手术HR+/HER2-乳腺癌术后患者,可考虑放疗与CDK4/6i同步给药,但需充分评估并密切监测毒性。
  • 同步给药期间应重点关注药疹等超敏反应,并全程监测因≥3级毒性导致的停药风险。

局限性

  • 为真实世界回顾性队列研究,存在回顾性设计固有偏倚。
  • 匹配后每组样本量为87例,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to compare the safety and toxicity profiles of concurrent versus sequential administration of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and postoperative radiotherapy (RT) in patients with Positive regional nodes, operable, hormone receptor-positive (HR+), HER2-negative breast cancer (HER2-). METHODS: We conducted a real-world, multicenter retrospective cohort study enrolling 364 patients with node-positive, operable HR+/HER2- breast cancer who received postoperative radiotherapy combined with CDK4/6 inhibitors between January 2019 and December 2024. Propensity score matching (PSM) was performed to balance baseline covariates between the two arms, yielding 87 patients in each matched group. The primary endpoint was permanent CDK4/6i discontinuation, and secondary endpoints included dose reduction, drug substitution, grade ≥3 toxicities, and symptomatic radiation-induced lung injury (sRILI). RESULTS: No significant intergroup differences were observed in CDK4/6i discontinuation rates before or after PSM (unmatched: 10.4% vs. 8.4%, P=0.536; PSM-matched: 10.3% vs. 9.2%, P=0.798). Similar non-significant findings were identified for dose reduction and drug substitution across unmatched and matched cohorts. For severe toxicities, univariate analysis of the unmatched cohort revealed a significantly higher rate of grade ≥3 drug eruption in the concurrent arm (4.3% vs. 0.4%, unadjusted P=0.013), while this association attenuated to borderline statistical significance after covariate balancing via PSM (4.6% vs. 0.0%, unadjusted P=0.059). No significant between-group differences were detected in sRILI, interstitial pneumonia, grade ≥3 radiation dermatitis, grade ≥3 diarrhea, or hematologic toxicities pre- and post-matching. All grade ≥3 drug eruptions occurred outside radiation fields and presented as diffuse maculopapular rashes involving the trunk and extremities, consistent with CDK4/6i-related hypersensitivity. CONCLUSIONS: Concurrent CDK4/6 inhibitor therapy and postoperative RT demonstrate a manageable safety and tolerance profile. Given that treatment discontinuation due to ≥G 3 toxicities was observed in both groups, close toxicity monitoring and comprehensive management throughout the treatment course should be implemented when combining RT with CDK4/6i.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Liu J, Lin X, Yu J, et al. Concurrent Versus Sequential Postoperative Radiotherapy and CDK4/6 Inhibitors in Breast Cancer with Positive Regional Nodes: A Multi-Center Safety and Toxicity Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 42913864. doi:10.1016/j.ijrobp.2026.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。